Welcome to our dedicated page for Caring Brands news (Ticker: CABR), a resource for investors and traders seeking the latest updates and insights on Caring Brands stock.
Caring Brands, Inc. (NASDAQ: CABR) is described as a wellness consumer products company focused on over-the-counter (OTC) and cosmetic products for hair, skin, and related health conditions. The news flow around CABR centers on product licensing, capital markets activity, and the development and commercialization of its wellness portfolio.
Company announcements highlight a growing portfolio of unique, patented, and clinically validated products for skin and hair growth, as well as treatments and protective products for conditions such as hair loss, eczema, psoriasis, vitiligo, burns, and jellyfish stings. News items also reference product candidates and concepts in sexual wellness and nausea relief.
One notable news theme is Caring Brands’ use of licensing and partnerships. The company has disclosed an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, an OTC nausea relief product. This type of announcement provides insight into how Caring Brands expands its product range and assumes responsibilities for manufacturing, marketing, sales strategy, and global distribution.
Another recurring topic in CABR news is capital markets activity. The company has reported an underwritten U.S. public offering and an uplisting of its common shares to the Nasdaq Capital Market under the symbol CABR, along with related registration and prospectus details.
Visitors to this news page can review press releases and other coverage related to Caring Brands’ product pipeline, licensing agreements, clinical and patent positioning, and stock market developments. For investors and observers interested in OTC wellness and cosmetic products, these updates provide context on how the company presents its strategy and operations over time.
Caring Brands (NASDAQ: CABR) announced issuance of two U.S. patents in January 2026 covering methods and compositions that increase sulfotransferase enzyme activity for its Hair Enzyme Booster technology. The patents broaden exclusive IP around enzyme-based topical hair loss treatments and support ongoing commercialization in the U.S. and via international licensees.
Caring Brands (Nasdaq: CABR) entered an exclusive worldwide license with Itonis to manufacture, market, and distribute Emesyl, an over-the-counter nausea relief product, effective Jan 5, 2026.
Under the agreement Caring Brands will assume global manufacturing, marketing, sales strategy, and distribution while Itonis will supply technical, formulation, historical sales, and IP information. The deal includes a royalty on future net sales and potential equity earn‑outs tied to revenue milestones. The release cites a QY Research market projection of USD 6.23 billion for nausea treatments in 2025. Caring Brands said it will provide further updates on timelines, manufacturing progress, and commercial rollout as initiatives advance.
Caring Brands (NASDAQ:CABR) closed an underwritten U.S. public offering of 1,000,000 shares at a public offering price of $4.00 per share for aggregate gross proceeds of approximately $4,000,000, before underwriting discounts and offering expenses.
The shares began trading on the Nasdaq Capital Market on November 13, 2025. The underwriter has a 45-day option to purchase up to an additional 150,000 shares at the public offering price, less discounts and commissions. The company intends to use net proceeds for general working capital, marketing and sales, and repayment of certain debt. Registration on Form S-1 (File No. 333-289767) was declared effective on October 30, 2025. D. Boral Capital LLC acted as sole underwriter.
Caring Brands (NASDAQ:CABR) priced an underwritten public offering of 1,000,000 common shares at $4.00 per share for gross proceeds of approximately $4,000,000, with a 45-day underwriter option to buy up to 150,000 additional shares. The offering is expected to close on November 14, 2025. The company received approval to list common shares on the Nasdaq Capital Market, with trading expected to begin on or around November 13, 2025, at which point shares will cease trading on the OTCQB. Proceeds are intended for general working capital, marketing and sales of proprietary products, and repayment of certain debt. The S-1 was declared effective on October 30, 2025.